Brendan Delaney

Brendan joined Constellation in January 2021 as Chief Commercial Officer.  He brings more than 25 years of global product strategy and launch experience to his role leading our commercial organization. Prior to joining Constellation, Brendan was the Chief Commercial Officer at Immunomedics, where he led the buildout of the marketing, sales, market access and commercial operations teams. He was instrumental in successfully launching Trodelvy, the first TROP-2 directed Antibody-drug conjugate for the treatment of triple-negative breast cancer. Previously, he served as Vice President of U.S. Hematology-Oncology at Celgene Corporation. Prior to joining Celgene, Brendan held various commercial roles at both Novartis Oncology and Genentech, where he led several successful product launches for blockbuster brands. He earned an MBA from the Stern School of Business at NYU and a B.A. in biology from Rutgers University.